Compare MRAM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | SLGL |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 247.1M |
| IPO Year | 2016 | 2016 |
| Metric | MRAM | SLGL |
|---|---|---|
| Price | $9.41 | $76.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 433.4K | 10.5K |
| Earning Date | 03-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.87 | $122.71 |
| Revenue Next Year | $8.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.34 | $0.40 |
| 52 Week High | $17.24 | $97.97 |
| Indicator | MRAM | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 53.95 |
| Support Level | $8.42 | $32.56 |
| Resistance Level | $9.74 | $96.99 |
| Average True Range (ATR) | 0.58 | 11.27 |
| MACD | 0.00 | -1.81 |
| Stochastic Oscillator | 28.25 | 51.89 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.